In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis

Baohong Ji, Nacer Lounis, Caroline Maslo, Chantal Truffot-Pernot, Pascale Bonnafous, Jacques Grosset

Research output: Contribution to journalArticle

Abstract

On 10% oleic acid-albumin-dextrose-catalase-enriched 7H11 agar medium, the MIC at which 90% of the isolates are inhibited for 20 strains of Mycobacterium tuberculosis was 0.5 μg of sparfloxacin (SPFX) or moxifloxacin (MXFX) per ml and 1.0 μg of clinafloxacin (CNFX) per ml, indicating that the in vitro activities of SPFX and MXFX were virtually identical and were slightly greater than that of CNFX. However, the in vivo activities of these drugs in a murine tuberculosis model differed considerably. Female Swiss mice were infected intravenously with 6.2 x 106 CFU of the H37Rv strain and treated for 4 weeks, beginning the next day after infection, with isoniazid (INH) serving as the positive control. By the criteria of 30-day survival rate, spleen weight, gross lung lesion, and mean number of CFU in the spleen, treatment with CNFX at up to 100 mg/kg of body weight six times weekly displayed no measurable effect against M. tuberculosis, whereas both SPFX and MXFX were effective; administration six times weekly of either of the latter two drugs demonstrated dosage-dependent bactericidal effects, as measured by enumeration of CFU in the spleens, and MXFX appeared more bactericidal than the same dosage of SPFX. Of the three fluoroquinolones, only MXFX at 100 mg/kg six times weekly appeared as bactericidal as INH at 25 mg/kg six times weekly. Thus, MXFX may be an important component of the newer combined regimens for treatment of tuberculosis.

Original languageEnglish (US)
Pages (from-to)2066-2069
Number of pages4
JournalAntimicrobial Agents and Chemotherapy
Volume42
Issue number8
StatePublished - Aug 1998
Externally publishedYes

Fingerprint

Mycobacterium tuberculosis
Spleen
Tuberculosis
Fluoroquinolones
Isoniazid
Oleic Acid
Pharmaceutical Preparations
Catalase
Agar
moxifloxacin
clinafloxacin
In Vitro Techniques
Albumins
Body Weight
Weights and Measures
Glucose
Lung
sparfloxacin
Infection

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Ji, B., Lounis, N., Maslo, C., Truffot-Pernot, C., Bonnafous, P., & Grosset, J. (1998). In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 42(8), 2066-2069.

In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. / Ji, Baohong; Lounis, Nacer; Maslo, Caroline; Truffot-Pernot, Chantal; Bonnafous, Pascale; Grosset, Jacques.

In: Antimicrobial Agents and Chemotherapy, Vol. 42, No. 8, 08.1998, p. 2066-2069.

Research output: Contribution to journalArticle

Ji, B, Lounis, N, Maslo, C, Truffot-Pernot, C, Bonnafous, P & Grosset, J 1998, 'In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis', Antimicrobial Agents and Chemotherapy, vol. 42, no. 8, pp. 2066-2069.
Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset J. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 1998 Aug;42(8):2066-2069.
Ji, Baohong ; Lounis, Nacer ; Maslo, Caroline ; Truffot-Pernot, Chantal ; Bonnafous, Pascale ; Grosset, Jacques. / In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. In: Antimicrobial Agents and Chemotherapy. 1998 ; Vol. 42, No. 8. pp. 2066-2069.
@article{8042bf8938f2417da70eeee894a8640e,
title = "In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis",
abstract = "On 10{\%} oleic acid-albumin-dextrose-catalase-enriched 7H11 agar medium, the MIC at which 90{\%} of the isolates are inhibited for 20 strains of Mycobacterium tuberculosis was 0.5 μg of sparfloxacin (SPFX) or moxifloxacin (MXFX) per ml and 1.0 μg of clinafloxacin (CNFX) per ml, indicating that the in vitro activities of SPFX and MXFX were virtually identical and were slightly greater than that of CNFX. However, the in vivo activities of these drugs in a murine tuberculosis model differed considerably. Female Swiss mice were infected intravenously with 6.2 x 106 CFU of the H37Rv strain and treated for 4 weeks, beginning the next day after infection, with isoniazid (INH) serving as the positive control. By the criteria of 30-day survival rate, spleen weight, gross lung lesion, and mean number of CFU in the spleen, treatment with CNFX at up to 100 mg/kg of body weight six times weekly displayed no measurable effect against M. tuberculosis, whereas both SPFX and MXFX were effective; administration six times weekly of either of the latter two drugs demonstrated dosage-dependent bactericidal effects, as measured by enumeration of CFU in the spleens, and MXFX appeared more bactericidal than the same dosage of SPFX. Of the three fluoroquinolones, only MXFX at 100 mg/kg six times weekly appeared as bactericidal as INH at 25 mg/kg six times weekly. Thus, MXFX may be an important component of the newer combined regimens for treatment of tuberculosis.",
author = "Baohong Ji and Nacer Lounis and Caroline Maslo and Chantal Truffot-Pernot and Pascale Bonnafous and Jacques Grosset",
year = "1998",
month = "8",
language = "English (US)",
volume = "42",
pages = "2066--2069",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "8",

}

TY - JOUR

T1 - In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis

AU - Ji, Baohong

AU - Lounis, Nacer

AU - Maslo, Caroline

AU - Truffot-Pernot, Chantal

AU - Bonnafous, Pascale

AU - Grosset, Jacques

PY - 1998/8

Y1 - 1998/8

N2 - On 10% oleic acid-albumin-dextrose-catalase-enriched 7H11 agar medium, the MIC at which 90% of the isolates are inhibited for 20 strains of Mycobacterium tuberculosis was 0.5 μg of sparfloxacin (SPFX) or moxifloxacin (MXFX) per ml and 1.0 μg of clinafloxacin (CNFX) per ml, indicating that the in vitro activities of SPFX and MXFX were virtually identical and were slightly greater than that of CNFX. However, the in vivo activities of these drugs in a murine tuberculosis model differed considerably. Female Swiss mice were infected intravenously with 6.2 x 106 CFU of the H37Rv strain and treated for 4 weeks, beginning the next day after infection, with isoniazid (INH) serving as the positive control. By the criteria of 30-day survival rate, spleen weight, gross lung lesion, and mean number of CFU in the spleen, treatment with CNFX at up to 100 mg/kg of body weight six times weekly displayed no measurable effect against M. tuberculosis, whereas both SPFX and MXFX were effective; administration six times weekly of either of the latter two drugs demonstrated dosage-dependent bactericidal effects, as measured by enumeration of CFU in the spleens, and MXFX appeared more bactericidal than the same dosage of SPFX. Of the three fluoroquinolones, only MXFX at 100 mg/kg six times weekly appeared as bactericidal as INH at 25 mg/kg six times weekly. Thus, MXFX may be an important component of the newer combined regimens for treatment of tuberculosis.

AB - On 10% oleic acid-albumin-dextrose-catalase-enriched 7H11 agar medium, the MIC at which 90% of the isolates are inhibited for 20 strains of Mycobacterium tuberculosis was 0.5 μg of sparfloxacin (SPFX) or moxifloxacin (MXFX) per ml and 1.0 μg of clinafloxacin (CNFX) per ml, indicating that the in vitro activities of SPFX and MXFX were virtually identical and were slightly greater than that of CNFX. However, the in vivo activities of these drugs in a murine tuberculosis model differed considerably. Female Swiss mice were infected intravenously with 6.2 x 106 CFU of the H37Rv strain and treated for 4 weeks, beginning the next day after infection, with isoniazid (INH) serving as the positive control. By the criteria of 30-day survival rate, spleen weight, gross lung lesion, and mean number of CFU in the spleen, treatment with CNFX at up to 100 mg/kg of body weight six times weekly displayed no measurable effect against M. tuberculosis, whereas both SPFX and MXFX were effective; administration six times weekly of either of the latter two drugs demonstrated dosage-dependent bactericidal effects, as measured by enumeration of CFU in the spleens, and MXFX appeared more bactericidal than the same dosage of SPFX. Of the three fluoroquinolones, only MXFX at 100 mg/kg six times weekly appeared as bactericidal as INH at 25 mg/kg six times weekly. Thus, MXFX may be an important component of the newer combined regimens for treatment of tuberculosis.

UR - http://www.scopus.com/inward/record.url?scp=0031879709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031879709&partnerID=8YFLogxK

M3 - Article

C2 - 9687408

AN - SCOPUS:0031879709

VL - 42

SP - 2066

EP - 2069

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 8

ER -